HYDERGINE
LOE ApproachingNDAORALSOLUTION
Approved
Jan 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is an oral solution small-molecule drug approved in 1981 with an unknown mechanism of action and indicated use. The specific therapeutic indication and patient population are not specified in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting a contracting team focused on managed decline and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an LOE-approaching lifecycle, HYDERGINE offers minimal near-term career growth potential. Roles available are primarily in managed decline, generic transition planning, and regulatory/patent defense rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.